Passage Bio, Inc. (PASG)
4.75
-0.29
(-5.75%)
USD |
NASDAQ |
Sep 18, 16:00
4.70
-0.05
(-1.05%)
After-Hours: 20:00
Passage Bio Enterprise Value : -8.870M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | -8.870M |
| September 17, 2026 | -7.937M |
| September 16, 2026 | -8.516M |
| September 15, 2026 | -8.806M |
| September 14, 2026 | -8.516M |
| September 11, 2026 | -8.066M |
| September 10, 2026 | -8.114M |
| September 09, 2026 | -8.259M |
| September 08, 2026 | -8.549M |
| September 04, 2026 | -9.192M |
| September 03, 2026 | -8.870M |
| September 02, 2026 | -9.321M |
| September 01, 2026 | -9.868M |
| August 31, 2026 | -9.900M |
| August 28, 2026 | -9.610M |
| August 27, 2026 | -10.22M |
| August 26, 2026 | -9.675M |
| August 25, 2026 | -8.613M |
| August 24, 2026 | -9.643M |
| August 21, 2026 | -9.868M |
| August 20, 2026 | -9.739M |
| August 19, 2026 | -9.643M |
| August 18, 2026 | -9.610M |
| August 17, 2026 | -9.546M |
| August 14, 2026 | -9.385M |
| Date | Value |
|---|---|
| August 13, 2026 | -9.434M |
| August 12, 2026 | -9.385M |
| August 11, 2026 | -9.675M |
| August 10, 2026 | -10.25M |
| August 07, 2026 | -9.997M |
| August 06, 2026 | -9.997M |
| August 05, 2026 | -9.321M |
| August 04, 2026 | -9.257M |
| August 03, 2026 | -9.707M |
| July 31, 2026 | -9.771M |
| July 30, 2026 | -9.707M |
| July 29, 2026 | -9.610M |
| July 28, 2026 | -9.450M |
| July 27, 2026 | -9.289M |
| July 24, 2026 | -8.259M |
| July 23, 2026 | -8.388M |
| July 22, 2026 | -8.323M |
| July 21, 2026 | -8.356M |
| July 20, 2026 | -8.677M |
| July 17, 2026 | -8.613M |
| July 16, 2026 | -8.356M |
| July 15, 2026 | -8.356M |
| July 14, 2026 | -9.868M |
| July 13, 2026 | -9.804M |
| July 10, 2026 | -9.450M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ARS Pharmaceuticals, Inc. | 361.52M |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.821M |
| Total Expenses (Quarterly) | 7.821M |
| EPS Diluted (Quarterly) | -2.437 |
| Earnings Yield | -238.2% |
| Normalized Earnings Yield | -233.75 |